# Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

> **NCT06365008** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 40 (estimated)

## Conditions studied

- Unresectable/Metastatic Gastric Cancer

## Interventions

- **DRUG:** Sintilimab+irinotecan+leucovorin folinate+fluorouracil

## Key facts

- **NCT ID:** NCT06365008
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2027-04-08
- **Final completion:** 2027-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365008, "Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06365008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*